Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
- PMID: 24516020
- DOI: 10.1200/JCO.2013.53.8199
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
Comment in
-
Reply to X. Qi et al.J Clin Oncol. 2014 Mar 20;32(9):968-9. doi: 10.1200/JCO.2013.54.3033. Epub 2014 Feb 10. J Clin Oncol. 2014. PMID: 24516037 No abstract available.
Comment on
-
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980084 Clinical Trial.
-
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
